# Clene (NASDAQ: CLNN) Reveals Important Findings From HEALEY ALS Platform Trial

* Clene presented findings on HEALEY ALS at the European Network for the Cure of ALS (ENCALS) meeting held in Stockholm, Sweden
* The presentation, titled “Long-Term CNM-Au8(R) Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,” showcased survival follow-up data
* CNM-Au8 was found to be safe and well-tolerated during the OLE

 Clene (NASDAQ: CLNN), through its wholly owned subsidiary, Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and safeguarding neuronal function to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). This week, Clene unveiled new and important long-term findings regarding CNM-Au8 treatment’s impact on survival rates and neurofilament light (“NfL”) levels from the HEALEY-ALS Platform Trial open label extension (“OLE”) at the European Network for the Cure of ALS (ENCALS) meeting held in Stockholm, Sweden (https://ibn.fm/xGfss).

 The presentation, titled “Long-Term CNM-Au8 Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,” showcased survival follow-up data extending up to 42 months (3.5 years) and long-term NfL biomarker results over 76 weeks. Analyses included…

 Read More>>

 NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

 Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

 The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

 Corporate Communications

 IBN (InvestorBrandNetwork)Los Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ult-prem/clene-nasdaq-clnn-reveals-important-findings-from-healey-als-platform-trial/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/clene-unveils-long-term-findings-on-cnm-au8-treatment-at-encals-meeting/6f2196d4c8bc527887ef1384f8d833cc) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1f2qrz5/clene_unveils_longterm_findings_on_cnmau8/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/248/27/riftsukT.webp)